Platelet function testing in acute cardiac care – is there a role for prediction or prevention of stent thrombosis and bleeding?

The role of platelet function testing in acute coronary syndrome patients undergoing percutaneous coronary intervention remains controversial despite the fact that high platelet reactivity is an independent predictor of stent thrombosis and emerging evidence suggests also a link between low platelet reactivity and bleeding. In this expert opinion paper, the Study Group on Biomarkers in Cardiology of the Acute Cardiovascular Care Association and the Working Group on Thrombosis of the European Society of Cardiology aim to provide an overview of current evidence in this area and recommendations for practicing clinicians.

[1]  Jeroen J. Bax,et al.  2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). , 2011, European heart journal.

[2]  A. Morton,et al.  Stability of VerifyNow P2Y12 assay results with citrate anticoagulation as compared to hirudin anticoagulation over 20-min period , 2015, Platelets.

[3]  I. Édes,et al.  Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods. , 2014, Thrombosis research.

[4]  V. Falk,et al.  Expert position paper on the management of antiplatelet therapy in patients undergoing coronary artery bypass graft surgery , 2014, European heart journal.

[5]  H. Schunkert,et al.  A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity , 2014, Thrombosis and Haemostasis.

[6]  D. Aradi,et al.  OPTIMIZING P2Y12-RECEPTOR INHIBITION IN ACUTE CORONARY SYNDROME PATIENTS BASED ON PLATELET FUNCTION TESTING: IMPACT OF PRASUGREL AND HIGH-DOSE CLOPIDOGREL , 2014 .

[7]  G. Veress,et al.  Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel. , 2014, Journal of the American College of Cardiology.

[8]  D. Sibbing,et al.  A model-based analysis of the clinical and economic impact of personalising P2Y12-receptor inhibition with platelet function testing in acute coronary syndrome patients , 2013, Thrombosis and Haemostasis.

[9]  K. Huber,et al.  Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention , 2013, European heart journal.

[10]  Deepak L. Bhatt,et al.  Consensus and update on the definition of on-treatment platelet reactivity to adenosine diphosphate associated with ischemia and bleeding. , 2013, Journal of the American College of Cardiology.

[11]  Deepak L. Bhatt,et al.  Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data , 2013, The Lancet.

[12]  Jeroen J. Bax,et al.  2013 ESC guidelines on the management of stable coronary artery disease: the Task Force on the management of stable coronary artery disease of the European Society of Cardiology. , 2013, European heart journal.

[13]  Peter L Duffy,et al.  Antiplatelets and AntithrombinsTCT-152 Is There a Therapeutic Window For Platelet Responsiveness Among PCI Patients? Analysis from the ADAPT-DES Study , 2013 .

[14]  M. Price,et al.  Efficacy and safety of intensified antiplatelet therapy on the basis of platelet reactivity testing in patients after percutaneous coronary intervention: systematic review and meta-analysis. , 2013, International journal of cardiology.

[15]  G. Maurer,et al.  Personalized antiplatelet treatment after percutaneous coronary intervention: the MADONNA study. , 2013, International journal of cardiology.

[16]  Peter L Duffy,et al.  Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study , 2013, The Lancet.

[17]  Eric Vicaut,et al.  Platelet function testing to adjust antiplatelet therapy for elective coronary stenting: a landmark analysis of the ARCTIC trial , 2013 .

[18]  A. Loundou,et al.  Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs). , 2013, JACC. Cardiovascular interventions.

[19]  C. Granger,et al.  Biomarkers in atrial fibrillation: a clinical review. , 2013, European heart journal.

[20]  S. Harding,et al.  Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate® analyser , 2013, Platelets.

[21]  I. Édes,et al.  New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals. , 2013, Thrombosis research.

[22]  G. Montalescot,et al.  Switching acute coronary syndrome patients from prasugrel to clopidogrel. , 2013, JACC. Cardiovascular interventions.

[23]  A. Morton,et al.  Hirudin anticoagulation allows more rapid determination of P2Y12 inhibition by the VerifyNow P2Y12 assay , 2013, Thrombosis and Haemostasis.

[24]  M. Price,et al.  Evaluating the clinical usefulness of platelet function testing: Considerations for the proper application and interpretation of performance measures , 2012, Thrombosis and Haemostasis.

[25]  D. Aradi,et al.  Impact of clopidogrel and potent P2Y12-inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention , 2012, Thrombosis and Haemostasis.

[26]  I. Xanthopoulou,et al.  Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment–Elevation Myocardial Infarction , 2012, Circulation. Cardiovascular interventions.

[27]  E. Vicaut,et al.  Bedside monitoring to adjust antiplatelet therapy for coronary stenting. , 2012, The New England journal of medicine.

[28]  D. Prabhakaran,et al.  Platelet function during extended prasugrel and clopidogrel therapy for patients with ACS treated without revascularization: the TRILOGY ACS platelet function substudy. , 2012, JAMA.

[29]  Howard K. Song,et al.  2012 update to the Society of Thoracic Surgeons guideline on use of antiplatelet drugs in patients having cardiac and noncardiac operations. , 2012, The Annals of thoracic surgery.

[30]  G. Lemesle,et al.  Relationship between post‐treatment platelet reactivity and ischemic and bleeding events at 1‐year follow‐up in patients receiving prasugrel , 2012, Journal of thrombosis and haemostasis : JTH.

[31]  Ankit Garg,et al.  Predictors of early, late, and very late stent thrombosis after primary percutaneous coronary intervention with bare-metal and drug-eluting stents for ST-segment elevation myocardial infarction. , 2012, JACC. Cardiovascular interventions.

[32]  D. Atar,et al.  ESC Guidelines for the Management of Acute Myocardial Infarction in Patients Presenting With ST-Segment Elevation , 2013 .

[33]  Jean-Claude Tardif,et al.  Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry , 2012, European heart journal.

[34]  G. Stone,et al.  A randomized trial of prasugrel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placem , 2012, Journal of the American College of Cardiology.

[35]  G. Maurer,et al.  Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS‐PCI study , 2012, Journal of thrombosis and haemostasis : JTH.

[36]  P. Rehak,et al.  Platelet Function Measurement–Based Strategy to Reduce Bleeding and Waiting Time in Clopidogrel-Treated Patients Undergoing Coronary Artery Bypass Graft Surgery: The Timing Based on Platelet Function Strategy to Reduce Clopidogrel-Associated Bleeding Related to CABG (TARGET-CABG) Study , 2012, Circulation. Cardiovascular interventions.

[37]  Peter L Duffy,et al.  IMPACT OF POINT–OF–CARE PLATELET FUNCTION TESTING AMONG PATIENTS WITH AND WITHOUT ACUTE CORONARY SYNDROMES UNDERGOING PCI WITH DRUG–ELUTING STENTS: AN ADAPT–DES SUBSTUDY , 2012 .

[38]  W. Wijns,et al.  A therapeutic window for platelet reactivity for patients undergoing elective percutaneous coronary intervention: results of the ARMYDA-PROVE (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty-Platelet Reactivity for Outcome Validation Effort) study. , 2012, JACC. Cardiovascular interventions.

[39]  P. Gurbel,et al.  High on‐treatment platelet reactivity assessed by various platelet function tests: is the consensus‐defined cut‐off of VASP‐P platelet reactivity index too low? , 2012, Journal of thrombosis and haemostasis : JTH.

[40]  Seung‐Jung Park,et al.  A point-of-care platelet function assay and C-reactive protein for prediction of major cardiovascular events after drug-eluting stent implantation. , 2011, Journal of the American College of Cardiology.

[41]  M. Price,et al.  Impact of platelet reactivity on clinical outcomes after percutaneous coronary intervention. A collaborative meta-analysis of individual participant data. , 2011, Journal of the American College of Cardiology.

[42]  S. Scott,et al.  Clinical, angiographic, and genetic factors associated with early coronary stent thrombosis. , 2011, JAMA.

[43]  Betti Giusti,et al.  High residual platelet reactivity after clopidogrel loading and long-term cardiovascular events among patients with acute coronary syndromes undergoing PCI. , 2011, JAMA.

[44]  P. Teirstein,et al.  Platelet Reactivity and Cardiovascular Outcomes After Percutaneous Coronary Intervention: A Time-Dependent Analysis of the Gauging Responsiveness With a VerifyNow P2Y12 Assay Impact on Thrombosis and Safety (GRAVITAS) Trial , 2011, Circulation.

[45]  T. Lauer,et al.  Kardiologische Aspekte der präoperativen Risikostratifizierung , 2011 .

[46]  D. Atar,et al.  Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology. , 2011, European heart journal.

[47]  M. Pansieri,et al.  High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syndromes. , 2011, Journal of the American College of Cardiology.

[48]  J. Marchesini,et al.  Prospective evaluation of on-clopidogrel platelet reactivity over time in patients treated with percutaneous coronary intervention relationship with gene polymorphisms and clinical outcome. , 2011, Journal of the American College of Cardiology.

[49]  G. Jakl,et al.  Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events , 2011, Thrombosis and Haemostasis.

[50]  N. Schork,et al.  Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. , 2011, JAMA.

[51]  S. Yusuf,et al.  Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. , 2010, The New England journal of medicine.

[52]  D. Aradi,et al.  Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: systematic review and meta-analysis. , 2010, American heart journal.

[53]  A. Kastrati,et al.  Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents. , 2010, American heart journal.

[54]  O. Morel,et al.  Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry. , 2010, JACC. Cardiovascular interventions.

[55]  C. Combescure,et al.  Clinical implications of clopidogrel non‐response in cardiovascular patients: a systematic review and meta‐analysis , 2010, Journal of thrombosis and haemostasis : JTH.

[56]  J. Eikelboom,et al.  Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study , 2010, Circulation.

[57]  V. Deneer,et al.  Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. , 2010, JAMA.

[58]  B. Giusti,et al.  Clopidogrel non-responsiveness and risk of cardiovascular morbidity , 2010, Thrombosis and Haemostasis.

[59]  A. Kastrati,et al.  Antiplatelet effects of clopidogrel and bleeding in patients undergoing coronary stent placement , 2010, Journal of thrombosis and haemostasis : JTH.

[60]  J. Geisel,et al.  The effect of a pneumatic tube transport system on platelet aggregation using optical aggregometry and the PFA-100. , 2010, Clinical laboratory.

[61]  Stefan Blankenberg,et al.  Sensitive troponin I assay in early diagnosis of acute myocardial infarction. , 2009, The New England journal of medicine.

[62]  P. Morange,et al.  Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients. , 2009, The American journal of cardiology.

[63]  Claes Held,et al.  Ticagrelor versus clopidogrel in patients with acute coronary syndromes. , 2009, The New England journal of medicine.

[64]  Adnan Kastrati,et al.  Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. , 2009, Journal of the American College of Cardiology.

[65]  M. Lordkipanidzé,et al.  Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. , 2008, European heart journal.

[66]  Matthew J Price,et al.  Prognostic significance of post-clopidogrel platelet reactivity assessed by a point-of-care assay on thrombotic events after drug-eluting stent implantation. , 2008, European heart journal.

[67]  E. Antman,et al.  Prasugrel Compared With High Loading– and Maintenance–Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation–Thrombolysis in Myocardial Infarction 44 Trial , 2007, Circulation.

[68]  G. Davı̀,et al.  Platelet activation and atherothrombosis. , 2007, The New England journal of medicine.

[69]  R. Blindt,et al.  The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis , 2007, Thrombosis and Haemostasis.

[70]  E. Antman,et al.  Prasugrel versus clopidogrel in patients with acute coronary syndromes. , 2007, The New England journal of medicine.

[71]  P. Morange,et al.  ADP-induced platelet aggregation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome , 2007, Thrombosis and Haemostasis.

[72]  A. Colombo,et al.  Incidence and Predictors of Drug-Eluting Stent Thrombosis During and After Discontinuation of Thienopyridine Treatment , 2007, Circulation.

[73]  P. Auquier,et al.  Vasodilator‐stimulated phosphoprotein phosphorylation analysis prior to percutaneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events , 2007, Journal of thrombosis and haemostasis : JTH.

[74]  Justin T. Newcomer,et al.  Evaluation of Dose-Related Effects of Aspirin on Platelet Function: Results From the Aspirin-Induced Platelet Effect (ASPECT) Study , 2007, Circulation.

[75]  Salim Yusuf,et al.  Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study , 2001, The Lancet.